Geneseeq uses NGS technologies to help physicians make meaningful decisions for cancer treatment.
Established in 2008, Geneseeq is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine.Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 25, 2019 | Series D | ¥800M | 2 | — | — | Detail |
Jul 21, 2017 | Series C | — | 2 | — | — | Detail |
Jun 1, 2016 | Series B | ¥60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
China Reform Holdings Corporation | — | Series D |
Lilly Asia Ventures | — | Series D |
Boyuanhongsheng | — | Series C |
Huatai Health Fund | — | Series C |
Eastern Investment | — | Series B |